Sanofi Is Weighing a Takeover of Insmed, Bloomberg Reports
A lung-drug maker valued at $26.28 billion would dwarf the French group's usual deal size, weeks after it told investors to expect bigger acquisitions.
1 sourced report in this file.
Verified identity
The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.
Market price
Latest quoteOpens Google
Coverage digest
TickerGrove has published 1 sourced report on INSMED Inc since Nov 19, 2026. The latest, published Nov 19, 2026, is “Sanofi Is Weighing a Takeover of Insmed, Bloomberg Reports”
A lung-drug maker valued at $26.28 billion would dwarf the French group's usual deal size, weeks after it told investors to expect bigger acquisitions.
TickerGrove coverage
Research foundation
Company analysis
Revenue is the top-line amount recognized from a company’s activities under its accounting policy.
Company analysis
This guide covers three statements: the income statement, the balance sheet and the cash-flow statement.
Investing basics
A stock is an ownership interest in one company.